Evidence of increasing frequency of herpes zoster management in Australian general practice since the introduction of a varicella vaccine

Medical Journal of Australia

Volumn 193, Issue 2, 2010, Pages 110-113

  Nelson, Mark R ^a   Britt, Helena C ^b   Harrison, Christopher M ^b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; VARICELLA ZOSTER VACCINE;

ARTICLE; AUSTRALIA; CHICKENPOX; GENERAL PRACTICE; GENERAL PRACTITIONER; HERPES ZOSTER; HUMAN; RETROSPECTIVE STUDY; VACCINATION;

EID: 77955726859     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2010.tb03818.x     Document Type: Article

References (17)

1. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20: 2500-2507. (Pubitemid 34615588)
2. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360: 678-682.
3. Marshall H, Ryan P, Roberton D. Uptake of varicella vaccine - a cross sectional survey of parental attitudes to nationally recommended but unfunded varicella immunisation. Vaccine 2005; 23: 5389-5397. (Pubitemid 41579310)
4. Macartney KK, Beutels P, McIntyre P, Burgess MA. Varicella vaccination in Australia. J Paediatr Child Health 2005; 41: 544-552.
5. MacIntyre CR, Chu CP, Burgess MA. Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiol Infect 2003; 131: 675-682.
6. Carville KS, Riddell MA, Kelly HA. A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia. Vaccine 2010; 28: 2532-2538.
7. Britt H, Miller GC, Charles J, et al. General practice activity in Australia 2008-09. Canberra: Australian Institute of Health and Welfare, 2009. (AIHW Cat. No. GEP 25.)
8. Classification Committee of the World Organization of Family Doctors. ICPC-2: International Classification of Primary Care. 2nd ed. Oxford: Oxford University Press, 1998.
9. Medicare Australia. Health statistics, Medicare Benefits Schedule. Canberra: Medicare Australia, 2009. www.medicareaustralia.gov.au/statistics/mbs- item.shtml (accessed Aug 2009).
10. Marin M, Güris D, Chaves SS, et al; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56 (RR-4): 1-40. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm (accessed Jun 2010).
11. Jumaan AO, Yu O, Jackson LA, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005;191: 2002-2007.
12. Mullooly JP, Riedlinger K, Chun C, et al. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 2005; 133: 245-253.
13. Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005; 20: 748-753.
14. Yih WK, Brooks DR, Lett SM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005; 5: 68. doi: 10.1186/1417-2458-5-68.
15. Chapman RS, Cross KW, Fleming DM. The incidence of shingles and its implications for vaccination policy. Vaccine 2003; 21: 2541-2547. (Pubitemid 36561347)
16. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-2284.
17. US National Institutes of Health. ClinicalTrials. gov. Zostavax™ administered concomitantly with Pneumovax™ 23. http://clinicaltrials.gov/ ct2/show/study/NCT00535730?sect=X6015 (accessed Jun 2010).